Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.6Last Year’s EPS
-3.04Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2025
|% Change Since: -25.58%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Agenus' significant progress in reducing operational costs and promising clinical outcomes from BOT/BAL trials, garnering external validation. However, financial challenges such as a reduced cash balance and net loss, along with the temporary shelving of pipeline products, were noted. Nonetheless, the strategic plans to monetize assets and focus on high-potential programs indicate a forward-looking approach.Company Guidance
In the recent earnings call, Agenus Inc. provided substantial guidance regarding its financial performance and strategic direction. The company reported a significant reduction in its annualized burn rate to approximately $50 million by mid-2025, aligning with its strategy to optimize resource allocation. Despite ending 2024 with a consolidated cash balance of $40.4 million, down from $76.1 million the previous year, Agenus remains committed to its revolutionary BOT/BAL program, which has demonstrated promising clinical outcomes in colorectal cancer. The company's revenue for 2024 was $103.5 million, with a net loss of $232.3 million or $10.59 per share. For Q4 2024, revenue stood at $26.8 million against a net loss of $46.8 million or $2.04 per share. Agenus is actively pursuing external partnerships and monetizing non-core assets to bolster its financial position while continuing to advance the BOT/BAL program, particularly in neoadjuvant settings for colorectal cancer.Significant Operational Burn Reduction
Agenus reduced its annualized operational burn to approximately $50 million by the middle of the year, aligning with their strategic cost reduction goals.
Promising Clinical Outcomes of BOT/BAL
BOT/BAL showed promising results in colorectal cancer, demonstrating durable responses and prolonged survival in refractory microsatellite stable colorectal cancer, offering potential revolutionary treatment options.
External Validation and Trials
Leading global oncology centers are independently conducting trials with BOT/BAL, reinforcing confidence in its potential benefits for patients.
Revenue Recognition
Agenus recognized revenue of $103.5 million for the year ended December 31, 2024.
Strategic Asset Monetization
Agenus is engaged in discussions for monetizing non-core assets, including its Emeryville manufacturing facility, to strengthen its financial position.
---
AGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 11, 2025 | $2.15 | $2.05 | -4.65% |
| Nov 12, 2024 | $3.90 | $3.10 | -20.51% |
| Aug 08, 2024 | $5.08 | $5.28 | +3.94% |
| May 07, 2024 | $12.95 | $12.01 | -7.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Agenus (AGEN) report earnings?
Agenus (AGEN) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Agenus (AGEN) earnings time?
Agenus (AGEN) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AGEN EPS forecast?
AGEN EPS forecast for the fiscal quarter 2025 (Q1) is -1.6.
---